Drug intelligence / Profile preview

Poldine

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous, Oral, Iontophoresis

Overview

Poldine is an anticholinergic drug that has been investigated for various therapeutic applications. It has been studied for its chemotherapeutic effects in combination with paclitaxel for advanced ovarian carcinoma. Additionally, poldine has been explored for its ability to inhibit gastric acid secretion, making it relevant for conditions like duodenal ulcers. Its anticholinergic properties also extend to reducing sweating, leading to its investigation in treating hyperhidrosis.

Brand names: Nacton
Other names: Poldine methylsulphate

Targets

M1 (Muscarinic acetylcholine receptor M1)CHRM3 (M3)CHRM2 (M2)

Beyond the preview

Go deeper on Poldine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poldine.

Explore the full profile